Want to see JP:4967 full AI Analyst Report?
Top Page
Kobayashi Pharmaceutical Co
(4967)
Select Model
Select Model
Rating:61Neutral
Price Target:
¥7,546.00
▲(35.57% Upside)
Action:Reiterated
Date:10/08/26
The score is held up by a very conservatively financed balance sheet and improved cash flow in 2025. Offsetting this, profitability has deteriorated sharply since 2023 and valuation is extremely rich (P/E ~327), while technicals show an uptrend but with overbought momentum that raises near-term risk.
Positive Factors
Conservative balance sheet
Minimal debt and a large, stable equity base provide substantial financial resilience. This reduces dependence on refinancing, preserves flexibility for product investment and marketing, and gives the company greater capacity to withstand earnings volatility over the next several quarters.
Negative Factors
Sharp profitability deterioration
The sustained decline in net income and operating profit materially weakens earnings quality despite the stable revenue base. Lower profitability can constrain reinvestment, reduce returns on equity and make the business more sensitive to execution challenges over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Minimal debt and a large, stable equity base provide substantial financial resilience. This reduces dependence on refinancing, preserves flexibility for product investment and marketing, and gives the company greater capacity to withstand earnings volatility over the next several quarters.
Read all positive factors
Kobayashi Pharmaceutical Co (4967) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥536.94B
Dividend Yield1.45%
Average Volume (3M)290.33K
Price to Earnings (P/E)330.6
Beta (1Y)0.34
Revenue Growth3.71%
EPS Growth-86.23%
CountryJP
Employees3,731
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)21.87
Shares Outstanding78,050,000
10 Day Avg. Volume261,950
30 Day Avg. Volume290,333
Financial Highlights & Ratios
PEG Ratio-1.73
Price to Book (P/B)1.91
Price to Sales (P/S)2.43
P/FCF Ratio32.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)139.7
Revenue Forecast (FY)¥171.81B
Kobayashi Pharmaceutical Co Business Overview & Revenue Model
Company Description
Kobayashi Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells OTC pharmaceuticals, guasi-drugs, deodorizing air fresheners, and sanitary products in Japan, the United States, Southeast Asia, and internationally. The co...
How the Company Makes Money
Kobayashi Pharmaceutical primarily makes money by selling branded, high-turnover consumer products across OTC health and household categories. Its core revenue model is product sales (recognized when products are shipped/sold through distribution ...
Kobayashi Pharmaceutical Co Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
92
Very Positive
Cash Flow
63
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 167.47B | 165.74B | 165.60B | 173.46B | 166.26B | 155.25B |
| Gross Profit | 84.16B | 84.71B | 87.60B | 96.38B | 92.33B | 88.77B |
| EBITDA | 11.26B | 12.52B | 21.96B | 33.65B | 33.33B | 32.49B |
| Net Income | 1.63B | 3.66B | 10.07B | 20.34B | 20.02B | 19.71B |
Balance Sheet | ||||||
| Total Assets | 251.89B | 275.33B | 265.37B | 267.47B | 255.83B | 252.55B |
| Cash, Cash Equivalents and Short-Term Investments | 57.33B | 70.61B | 65.75B | 79.84B | 104.53B | 109.05B |
| Total Debt | 723.00M | 678.00M | 846.00M | 987.00M | 792.00M | 630.00M |
| Total Liabilities | 42.19B | 64.32B | 51.89B | 62.66B | 57.93B | 56.95B |
| Stockholders Equity | 209.69B | 211.00B | 213.47B | 204.82B | 197.90B | 195.60B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 12.34B | -14.81B | 5.60B | 17.17B | 18.76B |
| Operating Cash Flow | 0.00 | 25.59B | 11.25B | 18.36B | 31.91B | 22.42B |
| Investing Cash Flow | 0.00 | -154.00M | -18.41B | -19.58B | -14.31B | 7.99B |
| Financing Cash Flow | 0.00 | -7.92B | -7.77B | -19.46B | -20.76B | -10.38B |
Kobayashi Pharmaceutical Co Technical Analysis
Positive
5566.00
Price Trends
6232.88
Positive
5884.76
Positive
5755.96
Positive
Market Momentum
305.47
Positive
68.63
Neutral
33.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4967, the sentiment is Positive. The current price of 5566 is below the 20-day moving average (MA) of 7061.35, below the 50-day MA of 6232.88, and below the 200-day MA of 5755.96, indicating a bullish trend. The MACD of 305.47 indicates Positive momentum. The RSI at 68.63 is Neutral, neither overbought nor oversold. The STOCH value of 33.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4967.
Kobayashi Pharmaceutical Co Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ¥671.75B | 19.68 | 11.29% | 1.73% | 9.67% | -2.92% | |
77 Outperform | ¥3.43T | 25.07 | 12.71% | 2.08% | 6.19% | 21.69% | |
76 Outperform | ¥511.05B | 17.52 | 8.98% | 1.58% | 6.21% | 37.97% | |
68 Neutral | ¥332.49B | 24.16 | 4.90% | 2.40% | 3.22% | 358.24% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
61 Neutral | ¥536.94B | 330.59 | 0.77% | 1.45% | 3.71% | -86.23% | |
58 Neutral | ¥1.44T | -68.40 | ― | 1.43% | 4.96% | -1485.59% |
* Consumer Defensive Sector Average
JP:4967
Kobayashi Pharmaceutical Co
7,150.00
1,939.89
37.23%
JP:4452
Kao
3,746.00
585.43
18.52%
JP:4922
Kose
5,891.00
-65.34
-1.10%
JP:4912
Lion
1,831.00
281.51
18.17%
JP:4527
Rohto Pharmaceutical Co
2,851.50
427.88
17.65%
JP:4911
Shiseido Company,Limited
3,569.00
838.87
30.73%
Kobayashi Pharmaceutical Co Corporate Events
Kobayashi Pharmaceutical Confirms Preliminary Take-Private Approach, No Decision Yet
Sep 24, 2026
Kobayashi Pharmaceutical has acknowledged that it received a preliminary, non-binding joint proposal from entities affiliated with Nippon Sangyo Suishin Kiko and CVC Capital Partners for a potential take-private transaction. The company clarified ...
Kobayashi Pharma to Divest Loss-Making China Unit in Strategic Shift
Aug 6, 2026
Kobayashi Pharmaceutical has decided to transfer all its equity interest in Jiangsu Kobayashi Pharmaceutical, a loss-making Chinese manufacturing subsidiary, to Venturepharma Pharmaceutical (Xiamen), resulting in Jiangsu Kobayashi ceasing to be an...
Kobayashi Pharmaceutical’s Profit Slumps Despite Higher Sales, Dividend Outlook Intact
Aug 6, 2026
Kobayashi Pharmaceutical reported a modest 2.5% rise in net sales to ¥70.7 billion for the six months ended June 30, 2026, but saw operating profit plunge 67.5% and profit attributable to owners of parent fall 64.1%. Despite weaker earnings, ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.